All articles by Jenna Philpott

Jenna Philpott

Jenna Philpott is a trainee healthcare and pharmaceutical reporter. Coming from a scientific background, Jenna has expertise in biochemistry, genetics and cancer science. Jenna previously wrote freelance articles focused on oncology and healthcare.

Phenomic scores two deals in two days with Boehringer and Astellas 

Phenomic will utilise its single-cell RNA transcriptomics programme to develop cancer therapies in collaborations with Astellas and Boehringer.

Generation Bio cuts 40% of staff in blow for non-viral gene therapy sector

The move is a strategic response amid challenges faced by the non-viral gene therapy sector, with several startups closing this year.

Eli Lilly advances small molecule drug portfolio with Prism Biolab partnership

Prism Biolab is entitled to receive development and commercial milestone payments of up to $660m from Lilly.

Pharma’s path to Net Zero: Targeting Scope 3 emissions 

With a target of net zero for 2050, pharmaceutical companies need to tackle scope 3 emissions, that make up the majority of their carbon footprint.

Novavax’s Omicron-targeting Covid-19 vaccine obtains WHO emergency listing  

The emergency use listing is based on non-clinical data where the vaccine demonstrated immune responses against variants in SARS-CoV-2.

AbbVie’s epcoritamab gets one step closer to follicular lymphoma approval 

The monoclonal antibody, approved to treat certain B-cell lymphomas, has received an FDA breakthrough therapy designation.

Novo Nordisk expands site to manufacture GLP-1 drugs

The expansion comes as Novo is trying to maintain strong growth in type 2 diabetes (T2D) after the launch of Eli Lilly’s Zepbound this month.

What’s in a name: Agencies struggle to keep up with expanding drug space 

With more approved drugs coming through than ever before, the need to avoid confusing names to ensure patient safety is important.

Simcere and Connect sign licensing agreement for anti IL-4Rα AD drug  

Simcere will have the rights to develop and commercialise rademikibart in mainland China, Macau, Taiwan, and Hong Kong.

FDA issues Cipla warning letter after thousands of complaints

The warning letter issued to Cipla will further delay the launch timelines of the company’s Advair generic in the US.